WO2017029820A1 - 放射性ハロゲン標識ピリド[1,2-a]ベンゾイミダゾール誘導体化合物 - Google Patents
放射性ハロゲン標識ピリド[1,2-a]ベンゾイミダゾール誘導体化合物 Download PDFInfo
- Publication number
- WO2017029820A1 WO2017029820A1 PCT/JP2016/055357 JP2016055357W WO2017029820A1 WO 2017029820 A1 WO2017029820 A1 WO 2017029820A1 JP 2016055357 W JP2016055357 W JP 2016055357W WO 2017029820 A1 WO2017029820 A1 WO 2017029820A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- carbon atoms
- compound
- labeled
- general formula
- Prior art date
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic System
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/0803—Compounds with Si-C or Si-Si linkages
- C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
- C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
- C07F7/0814—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring said ring is substituted at a C ring atom by Si
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Definitions
- the present invention relates to a radiohalogen-labeled pyrido [1,2-a] benzimidazole derivative compound or a salt thereof, and a radiopharmaceutical containing the same.
- AD Alzheimer's disease
- NFT neurofibrillary tangles
- Patent Document 1 describes a radioiodine-labeled compound of rhodanine and thiohydantoin derivatives having affinity for tau protein.
- Patent Documents 2 to 4 describe compounds having binding properties to both A ⁇ and tau protein. Specifically, Patent Document 2 discloses a radioiodine-labeled compound having styrylbenzimidazole as a mother nucleus, Patent Document 3 discloses benzimidazole pyrimidines, and Patent Document 4 discloses styrylbenzothiazole as a mother nucleus. Radioiodine labeled compounds are described.
- Patent Documents 1 to 4 have room for improvement as tau protein selective in vivo imaging agents.
- the present invention has been made in view of the above circumstances, and an object thereof is to provide a novel tau imaging agent capable of selectively imaging in vivo tau protein non-invasively by a nuclear medicine technique. .
- the present inventors have developed a tau protein by using a radiohalogen-labeled pyrido [1,2-a] benzimidazole derivative compound in which a substituent smaller than a phenyl group is introduced into a pyrido [1,2-a] benzimidazole skeleton.
- a radiohalogen-labeled pyrido [1,2-a] benzimidazole derivative compound in which a substituent smaller than a phenyl group is introduced into a pyrido [1,2-a] benzimidazole skeleton.
- One embodiment of the present invention provides a radiohalogen-labeled compound represented by the following general formula (1) or a salt thereof.
- one of R 1 and R 2 is a radioactive halogen atom, and the other is an alkyl group having 1 to 4 carbon atoms, an alkoxy group having 1 to 4 carbon atoms, an amino group, or a carbon number.
- Another aspect of the present invention provides a radiopharmaceutical containing the above-described radiohalogen-labeled compound or a salt thereof.
- an Alzheimer's disease diagnostic agent comprising the above-described radiohalogen-labeled compound or a salt thereof.
- Another aspect of the present invention provides a compound represented by the following general formula (2) or a salt thereof.
- one of R 3 and R 4 is a halogen atom, a trialkylstannyl group or a trialkylsilyl group, and the other is an alkyl group having 1 to 4 carbon atoms, 4 alkoxy groups, amino groups, alkylamino groups having 1 to 4 carbon atoms or dialkylamino groups having 2 to 4 carbon atoms.
- a radiohalogen-labeled compound represented by the above general formula (1) or a salt thereof is obtained from the compound represented by the above general formula (2) or a salt thereof by a radiohalogenation reaction.
- a method of manufacturing is provided.
- a novel tau imaging agent capable of selectively imaging a tau protein in a living body by a nuclear medicine technique can be provided.
- FIG. 7 is a diagram showing a synthesis example of 7-iodo-3-dimethylaminopyrido [1,2-a] benzimidazole (BIP-NMe 2 ) and a labeled precursor compound of radioactive iodine-labeled BIP-NMe 2 .
- FIG. 6 is a diagram showing a synthesis example of a labeled precursor compound of 7-iodo-3-methoxypyrido [1,2-a] benzimidazole (BIP-OMe) and radioactive iodine-labeled BIP-OMe.
- FIG. 7 is a diagram showing a synthesis example of a labeled precursor compound of 7-iodo-3-methylbenzo [4,5] imidazo [1,2-a] pyridine (BIP-Me) and radioactive iodine-labeled BIP-Me.
- FIG. 3 is a diagram showing a 125 I-labeled synthesis example of a radioactive iodine-labeled pyrido [1,2-a] benzimidazole derivative compound. It is a figure which shows the result of the immuno-staining using the autopsy brain tissue of an Alzheimer's disease patient, and in vitro autoradiography.
- A is the result of immunostaining of tau antibody using a brain tissue section of frontal lobe
- B is the result of immunostaining of A ⁇ antibody using a brain tissue section of frontal lobe
- C is the result of immunostaining of tau antibody using temporal lobe brain tissue sections
- D is the result of immunostaining of A ⁇ antibody using temporal lobe brain tissue sections.
- E shows the results of evaluation of [ 125 I] BIP-NMe 2 binding using frontal lobe brain tissue sections
- F shows [ 125 I] BIP-NMe 2 using temporal lobe brain tissue sections. The result of evaluating the binding property of is shown.
- G shows the results of evaluation of [ 125 I] BIP-OMe binding using frontal lobe brain tissue sections
- H shows [ 125 I] BIP-OMe binding using temporal lobe brain tissue sections. The result of having evaluated sex is shown.
- I shows the results of evaluation of [ 125 I] BIP-Me binding using frontal lobe brain tissue sections
- J shows [ 125 I] BIP-Me binding using temporal lobe brain tissue sections. The result of having evaluated sex is shown.
- the “radiohalogen atom” is at least one selected from the radioisotopes of fluorine, chlorine, bromine and iodine, preferably 18 F, 34 m Cl, 76 Br, 123 I, 124 I, 125 I or 131 I can be used.
- the “radioactive iodine atom” is not particularly limited as long as it is a radioactive isotope of iodine, but for nuclear medicine imaging such as positron emission tomography (PET) and single photon emission computed tomography (SPECT).
- PET positron emission tomography
- SPECT single photon emission computed tomography
- the radionuclide used is preferred, more preferably 123 I, 124 I, 125 I or 131 I, with 123 I being even more preferred for SPECT.
- the “alkyl group” may be linear or branched, but may be an alkyl group having 1 to 4 carbon atoms (methyl group, ethyl group, n-propyl group, isopropyl group, n-butyl group).
- Group, isobutyl group, tert-butyl group preferably an alkyl group having 1 to 3 carbon atoms (methyl group, ethyl group, n-propyl group, isopropyl group), more preferably 1 or 2 carbon atoms.
- An alkyl group (methyl group, ethyl group);
- alkoxy group is, in other words, an alkyl ether group, and “alkyl” here has the same meaning as the above-mentioned “alkyl group”.
- the “alkylamino group” is a group in which one hydrogen atom of an amino group (NH 2 ) is substituted with an alkyl group (NHR a (R a is an alkyl group)).
- the “dialkylamino group” is a group in which two hydrogen atoms of an amino group are each substituted with an alkyl group (NR a R b (R a and R b are each independently an alkyl group)). However, it has 2 to 4 carbon atoms.
- the “alkyl group” (R a , R b ) in the “alkylamino group” and “dialkylamino group” is also synonymous with the above-mentioned “alkyl group”.
- the radiohalogen-labeled compound represented by the general formula (1) may form a salt, such as an acid addition salt such as an inorganic acid salt (for example, hydrochloride, sulfate, hydrobromic acid). Salts, phosphates, etc.), organic acid salts (eg acetate, trifluoroacetate, succinate, maleate, fumarate, propionate, citrate, tartrate, lactate, oxalic acid Salt, methanesulfonate, p-toluenesulfonate, etc.). Further, the compound represented by the general formula (1) or a salt thereof may be a hydrate.
- an acid addition salt such as an inorganic acid salt (for example, hydrochloride, sulfate, hydrobromic acid). Salts, phosphates, etc.), organic acid salts (eg acetate, trifluoroacetate, succinate, maleate, fumarate, propionate, citrate, tartrate, lactate, oxalic
- R 1 is a radiohalogen atom
- R 2 is an alkyl group having 1 to 4 carbon atoms, or an alkoxy group having 1 to 4 carbon atoms.
- a radioactive halogen-labeled compound which is a dialkylamino group having 2 to 4 carbon atoms can be mentioned.
- radiohalogen-labeled compound examples include the following radioiodine-labeled compounds.
- Radioiodine labeled 7-iodo-3-amino-pyrido [1,2-a] benzimidazole in the above general formula (1), R 1 is a radioactive iodine atom and R 2 is an amino group) Compound)
- Radioactive iodine-labeled 7-iodo-3-methylaminopyrido [1,2-a] benzimidazole in the above general formula (1), R 1 is a radioactive iodine atom and R 2 is a methylamino group)
- Iodine labeled compound Radioactive iodine-labeled 7-iodo-3-dimethylaminopyrido [1,2-a] benzimidazole (in the above general formula (1), R 1 is a radioactive iodine atom and R 2 is a dimethylamino group
- Radioiodine labeled 7-methoxy-3-iodopyrido [1,2-a] benzimidazole radioiodine labeled compound in which R 1 is a methoxy group and R 2 is a radioactive iodine atom in the above general formula (1)
- Radioactive iodine-labeled 7-methyl-3-iodobenzo [4,5] imidazo [1,2-a] pyridine in the above general formula (1), R 1 is a methyl group and R 2 is a radioactive iodine atom
- Radioactive iodine labeling compound Radioactive iodine labeling compound
- the radiohalogen-labeled compound represented by the general formula (1) or a salt thereof can be obtained by performing a radiohalogenation reaction using the compound represented by the general formula (2) or a salt thereof.
- the “halogen atom” is at least one selected from a fluorine atom, a chlorine atom, a bromine atom, and an iodine atom.
- examples of the trialkylstannyl group include a tri (C1-C6 alkyl) stannyl group, and a tributylstannyl group is more preferable.
- examples of the trialkylsilyl group include a tri (C1-C6 alkyl) silyl group, and a trimethylsilyl group is more preferable.
- the compound represented by the general formula (2) may form a salt.
- a salt similar to the salt that can be formed by the radiohalogen-labeled compound represented by the general formula (1) can be employed.
- R 3 is a halogen atom, a trialkylstannyl group or a trialkylsilyl group
- R 4 is an alkyl having 1 to 4 carbon atoms.
- a group, an alkoxy group having 1 to 4 carbon atoms, an amino group, an alkylamino group having 1 to 4 carbon atoms, or a dialkylamino group having 2 to 4 carbon atoms should be prepared, for example, by a method according to Scheme 1. Can do.
- a 2-bromopyridine derivative having a substituent corresponding to R 4 in the general formula (2) at the 4-position contains copper (I) iodide, cesium carbonate and 1,10-phenanthroline in xylene. Dibromoaniline is allowed to act on the bottom.
- the bromo group may be substituted with a substituent corresponding to R 3 in the general formula (2).
- R 3 is an alkyl group having 1 to 4 carbon atoms, an alkoxy group having 1 to 4 carbon atoms, an amino group, or 1 carbon atom.
- An alkylamino group having 4 to 4 carbon atoms or a dialkylamino group having 2 to 4 carbon atoms in which R 4 is a halogen atom, a trialkylstannyl group or a trialkylsilyl group is prepared by, for example, the method according to Scheme 2 can do.
- o-bromoaniline having a substituent corresponding to R 3 in the general formula (2) at the meta position is added to xylene in the presence of copper (I) iodide, cesium carbonate and 1,10-phenanthroline. 2,4-dibromopyridine is allowed to act on.
- the bromo group may be substituted with a substituent corresponding to R 4 in the general formula (2).
- the radiohalogenation reaction may be performed using a radiohalogen prepared as an electrophile.
- the radiohalogenation reaction may be performed using a radiohalogen molecule or a radioacetyl acetyl hypohalide.
- the radioactive halogen molecule include a radioactive fluorine molecule, a radioactive chlorine molecule, a radioactive bromine molecule, and a radioactive iodine molecule.
- radioactive acetyl hypohalolide include radioactive acetyl hypofluoride, radioactive acetyl hypochloride, radioactive acetyl hypobromide, and radioactive acetyl hypoiodide.
- radioactive sodium halide or a radioactive potassium halide under acidic conditions in presence of an oxidizing agent.
- an oxidizing agent for example, chloramine-T, hydrogen peroxide solution, peracetic acid, halogenated succinimide and the like can be used.
- a radioactive iodine-labeled compound in which R 1 or R 2 is a radioactive iodine atom can be obtained.
- the radioiodination reaction is preferably performed by reacting an alkali metal radioiodide and an oxidizing agent under acidic conditions.
- alkali metal radioactive iodide for example, a sodium compound of radioactive iodine or a potassium compound of radioactive iodine can be used.
- oxidizing agent for example, chloramine-T, hydrogen peroxide solution, peracetic acid, N-chlorosuccinimide, N-bromosuccinimide and the like can be used.
- radioactive sodium iodide for example, [ 123 I] sodium iodide, [ 124 I] sodium iodide, [ 125 I] iodide in the presence of an oxidizing agent such as aqueous hydrogen peroxide under acidic conditions such as hydrochloric acid
- an oxidizing agent such as aqueous hydrogen peroxide under acidic conditions such as hydrochloric acid
- a radioiodination reaction can be performed to obtain a radioactive iodine-labeled compound in which R 1 or R 2 is a radioactive iodine atom in the general formula (1) .
- radiohalogen-labeled compound of general formula (1) When the obtained radiohalogen-labeled compound of general formula (1) is used as a radiopharmaceutical, unreacted radioiodine ions and insoluble impurities are purified by membrane filters, columns packed with various packing materials, HPLC, etc. It is desirable to do.
- the radiopharmaceutical according to the present invention can be defined as a formulation comprising a radiohalogen-labeled compound represented by the above general formula (1) or a salt thereof in a form suitable for administration into a living body.
- This radiopharmaceutical can be prepared as a liquid in which the radiohalogen-labeled compound of the general formula (1) obtained above is blended in water or physiological saline adjusted to an appropriate pH or Ringer's solution, if desired.
- the concentration of the present radiohalogen-labeled compound is preferably not more than a concentration at which the stability of the blended radiohalogen-labeled compound is obtained.
- the administration form of the radiopharmaceutical according to the present invention is preferably an injection, and the dose is not particularly limited as long as it is a concentration sufficient to image the distribution of the administered compound.
- the radiopharmaceutical of the present invention can be used as a diagnostic imaging agent for nuclear medicine examination, specifically, a diagnostic imaging agent for positron emission tomography (PET) or an image for single photon tomography (SPECT). It can be used for diagnostic agents.
- a diagnostic imaging agent for positron emission tomography PET
- SPECT single photon tomography
- It can be used for diagnostic agents.
- a positron emitting nuclide such as 18 F, 76 Br, 124 I or the like
- it can be used as an imaging diagnostic agent for positron emission tomography
- 123 I is used as a radioactive halogen atom
- Tau protein can be imaged by an image obtained by a nuclear medicine examination, and for example, Alzheimer's disease can be diagnosed noninvasively.
- BIP-NMe 2 7-iodo-3-dimethylaminopyrido [1,2-a] benzimidazole
- BIP-OMe 7-iodo-3-methoxypyrido [1,2-a] benzimidazole
- BIP-Me 7- Iodo-3-methylbenzo [4,5] imidazo [1,2-a] pyridine
- 125 I] BIP-NMe 2 7- [ 125 I] iodo-3-dimethylaminopyrido [1,2-a] benzo Imidazole [ 125 I]
- BIP-OMe 7- [ 125 I] iodo-3-methoxypyrido [1,2-a] benzimidazole [ 125 I]
- BIP-Me 7- [ 125 I] iodo-3-methylbenzo [4 , 5] imidazo [1,2-a] pyridine
- the medium pressure preparative liquid chromatograph includes an automatically set medium pressure preparative liquid chromatograph system (EPCLC-W-Prep 2XY; liquid feed pump (built-in mixer): No.
- detector (wavelength) Fraxed type: prep UV-254W, fraction collector: FR-260), HI-FLASH COLUMN (filler: silica gel SiOH, pore size: 60 ⁇ , particle size: 40 ⁇ m, column size: L or 2 L) and INJECT COLUMN (filler: silica gel SiOH, pore size: 60 ⁇ , particle size: 40 ⁇ m, column size: M or L) was attached.
- 1 H-NMR was measured using tetramethylsilane as an internal standard substance using a JNM-AL400 NMR apparatus manufactured by JEOL Ltd.
- Example 1 Synthesis of 7-tributylstannyl-3-dimethylaminopyrido [1,2-a] benzimidazole (labeled precursor compound of radioactive iodine-labeled BIP-NMe 2 ) According to the scheme shown in FIG. Then, a labeled precursor compound (compound 3) of radioactive iodine-labeled BIP-NMe 2 was obtained.
- Example 2 Synthesis of BIP-NMe 2 (Compound 4) A non-radioactive compound of BIP-NMe 2 (Compound 4) was obtained according to the scheme shown in FIG. Compound 3 (49.0 mg, 0.0979 mmol) synthesized according to the method shown in Example 1 was dissolved in chloroform (20.0 mL), and 2.50 mL of iodine in chloroform (50.0 mg / mL) was added at room temperature. Stir for 1.5 hours. The reaction was stopped with a saturated aqueous sodium hydrogensulfite solution, followed by extraction with chloroform (70.0 mL ⁇ 2). The organic layer was washed with saturated brine, dried over anhydrous magnesium sulfate, and the solvent was evaporated under reduced pressure.
- Example 4 Synthesis of BIP-OMe (Compound 7) A non-radioactive compound of BIP-OMe (Compound 7) was obtained according to the scheme shown in FIG. Compound 6 (37.9 mg, 0.0778 mmol) synthesized according to the method shown in Example 3 was dissolved in chloroform (10.0 mL), and iodine solution in chloroform (50.0 mg / mL) was added at room temperature. Stir for 1.5 hours. The reaction was stopped with a saturated aqueous sodium hydrogen sulfite solution, followed by extraction with chloroform (65.0 mL ⁇ 2). The organic layer was washed with saturated brine, dried over anhydrous magnesium sulfate, and the solvent was evaporated under reduced pressure.
- Example 6 Synthesis of BIP-Me (Compound 10) A non-radioactive compound of BIP-Me (Compound 10) was obtained according to the scheme shown in FIG. Compound 9 (12.9 mg, 0.0274 mmol) synthesized according to the method shown in Example 5 was dissolved in chloroform (13.0 mL), 400 ⁇ L of iodine chloroform solution (50.0 mg / mL) was added, and the mixture was stirred at room temperature for 1 hour. Stir. The reaction was stopped with a saturated aqueous sodium hydrogensulfite solution, followed by extraction with chloroform (40.0 mL ⁇ 2).
- Example 7 Synthesis of Radioiodine-Labeled BIP Derivative Compound [ 125 I] BIP-NMe 2 , [ 125 I] BIP-OMe, and [ 125 I] BIP-Me were obtained according to the scheme shown in FIG. Specifically, tin-iodine exchange was performed using Compound 3 synthesized according to the method shown in Example 1, Compound 6 synthesized according to the method shown in Example 3, and Compound 9 synthesized according to the method shown in Example 5, respectively. The reaction was labeled with radioactive iodine.
- [ 125 I] sodium iodide (3.7-7.4 MBq, specific activity 81.4 TBq / mmol) was added to 1 mol / L hydrochloric acid (100 ⁇ L) and 3% hydrogen peroxide (100 ⁇ L). Then, each ethanol solution of compound 3, 6, 9 (1.00 mg / mL or 2.00 mg / mL, 200 ⁇ L) was added. After reacting at room temperature for 40 minutes, a saturated sodium hydrogen sulfite aqueous solution (200 ⁇ L) was added as a reducing agent to stop the reaction.
- a saturated aqueous sodium hydrogen carbonate solution (200 ⁇ L) was added to neutralize the reaction solution, and the target product was extracted with ethyl acetate. After dehydrating through a column filled with anhydrous sodium sulfate, the solvent was distilled off. The resulting radioactive iodine-labeled compounds 4, 7, and 10 are purified using reversed-phase high-performance liquid chromatography (HPLC) using the corresponding non-radioactive compounds 4, 7, and 10 as samples, and the target product is extracted with ethyl acetate. did. After dehydrating through a column filled with anhydrous sodium sulfate, the solvent was distilled off.
- [ 125 I] BIP-NMe 2 , [ 125 I] BIP-OMe, and [ 125 I] BIP-Me were obtained with a radiochemical yield of 39 to 49% and a radiochemical purity of 99% or more.
- LC-20AD or LC-20AT manufactured by Shimadzu Corporation was used for HPLC, and ultraviolet spectrum detector SPD-20A as a detector and scintillation survey meter TCS-172 manufactured by Hitachi Aloka Medical Co., Ltd. or Universal Giken Co., Ltd.
- a HPLC radiation detector US-000T manufactured by HPLC was used.
- the column for reverse phase HPLC was COSMOSIL 5C18-AR-II 4.6 mmI. D. ⁇ 150 mm was used.
- the mobile phase and retention time of reverse phase HPLC are shown in Table 1.
- a 10 vol% ethanol aqueous solution (370 kBq / mL) of the radioiodine-labeled BIP derivative compound obtained by the method shown in Example 7 was added and incubated at room temperature for 2 hours. After washing with a 50% by volume ethanol aqueous solution (1 hour ⁇ 1), the plate was exposed to an imaging plate (BAS-SR2025 manufactured by Fuji Film Co., Ltd.), and then a bioimaging analyzer (Bio-Merging Analyzer BAS-5000 manufactured by Fuji Film Co., Ltd.) Analysis was carried out. For quantitative analysis, Multi Gauge manufactured by Fuji Film Co., Ltd. was used.
- FIG. 5 shows the result.
- Figure 5E, F shows the results of using the [125 I] BIP-NMe 2
- Figure 5G, H shows the result of using the [125 I] BIP-OMe
- FIG 5I, J is [125 I ]
- the result using BIP-Me is shown.
- 5E, G, and I show the results using the frontal lobe brain tissue section
- FIGS. 5F, H, and J show the results using the temporal lobe brain tissue section.
- [ 125 I] BIP-NMe 2 , [ 125 I] BIP-OMe, and [ 125 I] BIP-Me all show radioactive accumulation in brain tissue sections of the frontal lobe.
- Histofine Simple Stain MAX-PO (MULTI) (manufactured by Nichirei Bioscience) was reacted at room temperature for 30 minutes and then washed with PBS-Tween 20 (3 minutes ⁇ 3) and TBS (5 minutes ⁇ 1). Finally, it was reacted with the DAB solution at room temperature for 1 minute. The reaction was stopped by washing with distilled water (1 minute ⁇ 1). After enclosing the brain tissue section, the brain tissue section was observed with a microscope (BZ-9000 manufactured by Keyence Corporation).
- FIG. 5 shows the result. 5A and 5B show the results using the frontal lobe brain tissue section, and FIGS. 5C and 5D show the results using the temporal lobe brain tissue section.
- FIGS. 5A and 5C show the results of immunostaining of tau antibody
- FIGS. 5B and 5D show the results of immunostaining of A ⁇ antibody.
- the accumulation of radioactivity on brain tissue sections in temporal lobes showed an increase in tau accumulation compared to A ⁇ accumulation. From the correspondence, it is clear that each compound of [ 125 I] BIP-NMe 2 , [ 125 I] BIP-OMe and [ 125 I] BIP-Me clearly shows tau accumulated in AD brain. It became.
- in vitro autoradiographic evaluation is performed according to the method shown in Evaluation 1, and it is confirmed that the compound has binding selectivity to tau accumulated in AD brain.
- normal mouse body radioactivity distribution evaluation is performed according to the method shown in Evaluation 2 using these 125 I-labeled compounds to confirm brain transferability and subsequent disappearance from the brain.
- radiohalogen-labeled compound according to the present invention can selectively and non-invasively image brain tau protein.
Abstract
Description
また、本発明において「ジアルキルアミノ基」は、アミノ基の2つの水素原子がそれぞれアルキル基で置換された基(NRaRb(Ra、Rbが各々独立してアルキル基である))であるが、炭素数2~4のものである。
なお、「アルキルアミノ基」及び「ジアルキルアミノ基」における「アルキル基」(Ra、Rb)もまた、前述した「アルキル基」と同義である。
・放射性ヨウ素標識7-ヨード-3-アミノ-ピリド[1,2-a]ベンゾイミダゾール(上記一般式(1)中、R1が放射性ヨウ素原子であり、R2がアミノ基である放射性ヨウ素標識化合物)
・放射性ヨウ素標識7-ヨード-3-メチルアミノピリド[1,2-a]ベンゾイミダゾール(上記一般式(1)中、R1が放射性ヨウ素原子であり、R2がメチルアミノ基である放射性ヨウ素標識化合物)
・放射性ヨウ素標識7-ヨード-3-ジメチルアミノピリド[1,2-a]ベンゾイミダゾール(上記一般式(1)中、R1が放射性ヨウ素原子であり、R2がジメチルアミノ基である放射性ヨウ素標識化合物)
・放射性ヨウ素標識7-ヨード-3-メトキシピリド[1,2-a]ベンゾイミダゾール(上記一般式(1)中、R1が放射性ヨウ素原子であり、R2がメトキシ基である放射性ヨウ素標識化合物)
・放射性ヨウ素標識7-ヨード-3-メチルベンゾ[4,5]イミダゾ[1,2-a]ピリジン(上記一般式(1)中、R1が放射性ヨウ素原子であり、R2がメチル基である放射性ヨウ素標識化合物)
・放射性ヨウ素標識7-アミノ-3-ヨードピリド[1,2-a]ベンゾイミダゾール(上記一般式(1)中、R1がアミノ基であり、R2が放射性ヨウ素原子である放射性ヨウ素標識化合物)
・放射性ヨウ素標識7-メチルアミノ-3-ヨードピリド[1,2-a]ベンゾイミダゾール(上記一般式(1)中、R1がメチルアミノ基であり、R2が放射性ヨウ素原子である放射性ヨウ素標識化合物)
・放射性ヨウ素標識7-ジメチルアミノ-3-ヨードピリド[1,2-a]ベンゾイミダゾール(上記一般式(1)中、R1がジメチルアミノ基であり、R2が放射性ヨウ素原子である放射性ヨウ素標識化合物)
・放射性ヨウ素標識7-メトキシ-3-ヨードピリド[1,2-a]ベンゾイミダゾール(上記一般式(1)中、R1がメトキシ基であり、R2が放射性ヨウ素原子である放射性ヨウ素標識化合物)
・放射性ヨウ素標識7-メチル-3-ヨードベンゾ[4,5]イミダゾ[1,2-a]ピリジン(上記一般式(1)中、R1がメチル基であり、R2が放射性ヨウ素原子である放射性ヨウ素標識化合物)
BIP-NMe2:7-ヨード-3-ジメチルアミノピリド[1,2-a]ベンゾイミダゾール
BIP-OMe:7-ヨード-3-メトキシピリド[1,2-a]ベンゾイミダゾール
BIP-Me:7-ヨード-3-メチルベンゾ[4,5]イミダゾ[1,2-a]ピリジン
[125I]BIP-NMe2:7-[125I]ヨード-3-ジメチルアミノピリド[1,2-a]ベンゾイミダゾール
[125I]BIP-OMe:7-[125I]ヨード-3-メトキシピリド[1,2-a]ベンゾイミダゾール
[125I]BIP-Me:7-[125I]ヨード-3-メチルベンゾ[4,5]イミダゾ[1,2-a]ピリジン
また、本実施例において、「室温」は25℃である。
各化合物の合成例において、化合物合成における各ステップは、必要に応じて複数回繰り返し行い、他の合成において中間体等として用いる際に必要な量を確保した。
放射能の測定にはパーキンエルマー株式会社製のWallac WIZARD 1480を用いた。
図1に示すスキームに沿って、放射性ヨウ素標識BIP-NMe2の標識前駆体化合物(化合物3)を得た。
Org Biomol Chem,11,8073,2013の方法を基に合成を行い、化合物1を収量1.10g(54.6%)で得た。
化合物1(1.10g,5.46mmol)をキシレン(45.0mL)に溶解し、2,5-ジブロモアニリン(1.37g,5.46mmol)、ヨウ化銅(I)(208mg,1.09mmol)、炭酸セシウム(5.34g,16.4mmol)及び1,10-フェナントロリン(393mg,2.18mmol)を加えた後、撹拌下、72時間加熱還流した。反応溶液を室温に戻し、クロロホルム(70mL×2)で抽出した。有機層を飽和食塩水で洗浄した後、無水硫酸マグネシウムで脱水し、溶媒を減圧留去した。残渣をクロロホルム/メタノール(20/1)を溶出溶媒とするシリカゲルカラムクロマトグラフィーに付し、化合物2を収量94.9mg(6.00%)で得た。
1H-NMR(400MHz,重クロロホルム)δ 8.16(d,J=7.5Hz,1H),7.86(s,1H),7.56(d,J=8.7Hz,1H),7.30(d,J=8.7Hz,1H),6.60(d,J=7.5Hz,1H),6.55(s,1H),3.14(s,6H)。
MS(ESI)m/z 290.1[MH+]。
化合物2(94.9mg,0.327mmol)を1,4-ジオキサン(30.0mL)に溶解し,ビス(トリブチルスズ)(655μL,1.31mmol)、テトラキストリフェニルホスフィンパラジウム(163mg,0.141mmol)、トリエチルアミン(10.0mL)及びジメチルホルムアミド(8mL)を加えて、撹拌下、5.5時間加熱還流した。反応溶液を室温に戻し、クロロホルム(90mL×2)で抽出した。有機層を飽和食塩水で洗浄した後、無水硫酸マグネシウムで脱水し、溶媒を減圧留去した。残渣をクロロホルム/メタノール(15/1)を溶出溶媒とするシリカゲルカラムクロマトグラフィーに付し、化合物3を収量18.0mg(11.0%)で得た。
1H-NMR(400MHz,重メタノール)δ 8.41(d,J=7.5Hz,1H),7.81(d,J=7.8Hz,1H),7.66(s,1H),7.24(d,J=7.5Hz,1H),6.65(dd,J=7.8,2.6Hz,1H),6.32(d,J=2.3Hz,1H),3.06(s,6H),1.56-1.63(m,6H),1.32-1.41(m,6H),1.10-1.14(m,6H),0.88-0.92(m,9H)。
MS(ESI)m/z 502.4[MH+]。
図1に示すスキームに沿って、BIP-NMe2の非放射性化合物(化合物4)を得た。
実施例1に示す方法に従って合成した化合物3(49.0mg,0.0979mmol)をクロロホルム(20.0mL)に溶解し、ヨウ素のクロロホルム溶液(50.0mg/mL)を2.50mL加えて室温で1.5時間撹拌した。飽和亜硫酸水素ナトリウム水溶液で反応を停止した後、クロロホルム(70.0mL×2)で抽出した。有機層を飽和食塩水で洗浄した後、無水硫酸マグネシウムで脱水し、溶媒を減圧留去した。残渣をクロロホルム/メタノール(20/1)を溶出溶媒とするシリカゲルカラムクロマトグラフィーに付し、BIP-NMe2を収量5.50mg(16.7%)で得た。
1H-NMR(400MHz,重メタノール)δ 8.75(d,J=7.8Hz,1H),7.94(s,1H),7.85(d,J=8.7Hz,1H),7.72(d,J=8.4Hz,1H),7.08(d,J=7.8Hz,1H),6.56(s,1H),3.25(s,6H)。
HRMS(EI)m/z calcd for C13H12IN3(M+)337.0076,found 337.0074。
図2に示すスキームに沿って、放射性ヨウ素標識BIP-OMeの標識前駆体化合物(化合物6)を得た。
2-ブロモ-4-メトキシピリジン(1.23mL,10.0mmol)をキシレン(50.0mL)に溶解し,2,5-ジブロモアニリン(2.51g,10.0mmol)、ヨウ化銅(I)(381mg,2.00mmol)、炭酸セシウム(9.78g,30.0mmol)及び1,10-フェナントロリン(721mg,4.00mmol)を加えた後、撹拌下、75時間加熱還流した。反応溶液を室温に戻し、クロロホルム(120mL×2)で抽出した。有機層を飽和食塩水で洗浄した後、無水硫酸マグネシウムで脱水し、溶媒を減圧留去した。残渣をクロロホルム/メタノール(49/1)を溶出溶媒とするシリカゲルカラムクロマトグラフィーに付し、化合物5を収量223mg(8.05%)で得た。
1H-NMR(400MHz,重クロロホルム)δ 8.21(d,J=7.5Hz,1H),7.95(d,J=1.7Hz,1H),7.63(d,J=8.7Hz,1H),7.34(dd,J=8.4,1.7Hz,1H),6.87(d,J=2.3Hz,1H),6.59(dd,J=7.5,2.6Hz,1H),3.93(s,3H)。
MS(ESI)m/z 277.1[MH+]。
化合物5(114mg,0.411mmol)を1,4-ジオキサン(30.0mL)に溶解し、ビス(トリブチルスズ)(827μL,1.65mmol)、テトラキストリフェニルホスフィンパラジウム(204mg,0.177mmol)及びトリエチルアミン(15.0mL)を加えて、撹拌下、2.5時間加熱還流した。反応終了後、溶媒を減圧留去した。残渣をクロロホルム/メタノール(49/1)を溶出溶媒とするシリカゲルカラムクロマトグラフィーに付し、化合物6を収量47.9mg(23.9%)で得た。
1H-NMR(400MHz,重クロロホルム)δ 8.24(d,J=7.5Hz,1H),7.95(s,1H),7.75(d,J=7.5Hz,1H),7.36(d,J=7.8Hz,1H),6.86(d,J=2.3Hz,1H),6.54(dd,J=7.2,2.3Hz,1H),3.93(s,6H),1.54-1.60(m,6H),1.32-1.37(m,6H),1.09-1.13(m,6H),0.87-0.90(m,9H)。
MS(ESI)m/z 489.3[MH+]。
図2に示すスキームに沿って、BIP-OMeの非放射性化合物(化合物7)を得た。
実施例3に示す方法に従って合成した化合物6(37.9mg,0.0778mmol)をクロロホルム(10.0mL)に溶解し、ヨウ素のクロロホルム溶液(50.0mg/mL)を1.00mL加えて室温で1.5時間撹拌した。飽和亜硫酸水素ナトリウム水溶液で反応を停止した後、クロロホルム(65.0mL×2)で抽出した。有機層を飽和食塩水で洗浄した後、無水硫酸マグネシウムで脱水し、溶媒を減圧留去した。残渣を酢酸エチル/ヘキサン(2/1)を溶出溶媒とするシリカゲルカラムクロマトグラフィーに付し、BIP-OMeを収量14.2mg(56.3%)で得た。
1H-NMR(400MHz,重クロロホルム)δ 8.20(d,J=7.5Hz,1H),8.17(d,J=1.2Hz,1H),7.51-7.57(m,2H),6.86(d,J=2.3Hz,1H),6.56(dd,J=7.5,2.3Hz,1H),3.93(s,6H)。
HRMS(EI)m/z calcd for C12H9IN2O(M+)323.9760,found 323.9762。
図3に示すスキームに沿って、放射性ヨウ素標識BIP-Meの標識前駆体化合物(化合物9)を得た。
2-ブロモ-4-メチルピリジン(135μL,1.20mmol)をキシレン(8.00mL)に溶解し、2,5-ジブロモアニリン(251mg,1.00mmol)、ヨウ化銅(I)(38.1mg,0.20mmol)、炭酸セシウム(978mg,3.00mmol)及び1,10-フェナントロリン(72.1mg,0.40mmol)を加えた後、撹拌下、57.5時間加熱還流した。反応溶液を室温に戻し、クロロホルム(65mL×2)で抽出した。有機層を飽和食塩水で洗浄した後、無水硫酸マグネシウムで脱水し、溶媒を減圧留去した。残渣を酢酸エチル/ヘキサン(1/1)を溶出溶媒とするシリカゲルカラムクロマトグラフィーに付し、化合物8を収量62.4mg(23.9%)で得た。
1H-NMR(400MHz,重クロロホルム)δ 8.28(d,J=7.0Hz,1H),8.02(s,1H),7.70(d,J=8.7Hz,1H),7.40-7.43(m,2H),6.72(d,J=7.0Hz,1H),2.48(s,3H)。
MS(ESI)m/z 261.1[MH+]。
化合物8(62.4mg,0.239mmol)を1,4-ジオキサン(14.0mL)に溶解し、ビス(トリブチルスズ)(240μL,0.478mmol)、テトラキストリフェニルホスフィンパラジウム(119mg,0.103mmol)及びトリエチルアミン(7.00mL)を加えて、撹拌下、2.5時間加熱還流した。反応終了後,溶媒を減圧留去した。残渣を酢酸エチル/ヘキサン(1/1)を溶出溶媒とするシリカゲルカラムクロマトグラフィーに付し、化合物9を収量14.9mg(13.2%)で得た。
1H-NMR(400MHz,重クロロホルム)δ 8.31(d,J=7.0Hz,1H),8.02(s,1H),7.82(d,J=7.8Hz,1H),7.38-7.42(m,2H),6.66(d,J=7.0Hz,1H),2.46(s,3H),1.53-1.61(m,6H),1.32-1.39(m,6H),1.10-1.14(m,6H),0.86-0.91(m,9H)。
MS(ESI)m/z 473.3[MH+]。
図3に示すスキームに沿って、BIP-Meの非放射性化合物(化合物10)を得た。
実施例5に示す方法に従って合成した化合物9(12.9mg,0.0274mmol)をクロロホルム(13.0mL)に溶解し、ヨウ素のクロロホルム溶液(50.0mg/mL)を400μL加えて室温で1時間撹拌した。飽和亜硫酸水素ナトリウム水溶液で反応を停止した後、クロロホルム(40.0mL×2)で抽出した。有機層を飽和食塩水で洗浄した後、無水硫酸マグネシウムで脱水し、溶媒を減圧留去した。残渣を酢酸エチル/ヘキサン(1/1)を溶出溶媒とするシリカゲルカラムクロマトグラフィーに付し、BIP-Meを収量5.5mg(65.2%)で得た。
1H-NMR(400MHz,重クロロホルム)δ 8.29(d,J=7.0Hz,1H),8.24(d,J=1.2Hz,1H),7.60(s,2H),7.43(s,1H),6.72(d,J=7.2Hz,1H),2.49(s,3H)。
HRMS(EI)m/z calcd for C12H9IN2(M+)307.9811,found 307.9808。
図4に示すスキームに沿って、[125I]BIP-NMe2、[125I]BIP-OMe、[125I]BIP-Meを得た。具体的には、実施例1に示す方法に従って合成した化合物3、実施例3に示す方法に従って合成した化合物6、及び、実施例5に示す方法に従って合成した化合物9をそれぞれ用い、スズ-ヨウ素交換反応により放射性ヨウ素標識した。より具体的には、1mol/L塩酸(100μL)及び3%過酸化水素水(100μL)に[125I]ヨウ化ナトリウム(3.7-7.4MBq、比放射能81.4TBq/mmol)を添加し、化合物3、6、9の各エタノール溶液(1.00mg/mLあるいは2.00mg/mL,200μL)をそれぞれ加えた。室温で40分間反応させた後,還元剤として飽和亜硫酸水素ナトリウム水溶液(200μL)を加え,反応を停止した。飽和炭酸水素ナトリウム水溶液(200μL)を加えて反応液を中和した後,酢酸エチルで目的物を抽出した。無水硫酸ナトリウムを充填したカラムを通し脱水した後,溶媒を留去した。得られた放射性ヨウ素標識化合物4、7、10は,対応する非放射性化合物4、7、10を標品として逆相高速液体クロマトグラフィー(HPLC)を用いて精製し、酢酸エチルで目的物を抽出した。無水硫酸ナトリウムを充填したカラムを通し脱水した後,溶媒を留去した。
[125I]BIP-NMe2、[125I]BIP-OMe、[125I]BIP-Meの各化合物を放射化学的収率39~49%,放射化学的純度99%以上で得た。
なお、HPLCには,株式会社島津製作所製LC-20ADあるいはLC-20ATを使用し、検出器として紫外スペクトル検出器SPD-20Aと日立アロカメディカル株式会社製シンチレーションサーベイメーターTCS-172あるいはユニバーサル技研株式会社製HPLC用放射線検出器US-000Tを使用した。逆相HPLC用カラムには,ナカライテスク株式会社製COSMOSIL 5C18-AR-II 4.6mmI.D.×150mmを使用した。逆相HPLCの移動相及び保持時間は表1に示す。
(1)インビトロオートラジオグラフィー
アルツハイマー病(AD)患者剖検脳組織切片(76歳,男性,前頭葉部位と、側頭葉部位のもの,6μm)は、京都大学医学研究科及び国立循環器病研究センター病院より提供されたものを使用した。キシレン洗浄(15分×2)、エタノール(1分×2)、90体積%エタノール水溶液(1分×1)、80体積%エタノール水溶液(1分×1)、70体積%エタノール水溶液(1分×1)及び精製水洗浄(2.5分×2)をすることで脱パラフィン処理を行った。実施例7に示す方法で得られた放射性ヨウ素標識BIP誘導体化合物の10体積%エタノール水溶液(370kBq/mL)を添加し、室温で2時間インキュベートした。50体積%エタノール水溶液(1時間×1)で洗浄後、イメージングプレート(富士フィルム株式会社製BAS-SR2025)に露光させ、バイオイメージングアナライザー(富士フィルム株式会社製バイオーメージングアナライザーBAS-5000)にて分析を行った。定量解析には富士フィルム株式会社製Multi Gaugeを使用した。
オートラジオグラフィーで使用したAD剖検組織脳切片に隣接切片を用いて、タウ及びAβの免疫染色を行った。タウの免疫染色における一次抗体には、抗リン酸化タウモノクローナル抗体(AT8,Thermo Scientfic社製)を、Aβの免疫染色における1次抗体には、抗Aβ1-42モノクローナル抗体(BC05,WAKO社製)を用いた。キシレン洗浄(15分×2)、エタノール(1分×2)、90体積%エタノール水溶液(1分×1)、80体積%エタノール水溶液(1分×1)、70体積%エタノール水溶液(1分×1)及び精製水洗浄(2.5分×2)することで脱パラフィン処理を行った。抗原の賦活化には0.01mol/Lクエン酸緩衝液(pH6.0)中におけるオートクレーブ(15分)及び蟻酸処理(5分)を行った。流水で洗浄(5分)した後、PBS-Tween20(2分×1)で洗浄した。1次抗体溶液と室温で1時間反応させた後、PBS-Tween20(5分×3)で洗浄した。ヒストファイン シンプルステイン MAX-PO(MULTI)(ニチレイバイオサイエンス社製)と室温で30分間反応させた後、PBS-Tween20(3分×3)およびTBS(5分×1)で洗浄した。最後に、DAB溶液と室温で1分間反応させた。蒸留水(1分×1)で洗浄し反応を停止させた。脳組織切片を封入した後に顕微鏡(株式会社キーエンス製BZ-9000)で観察した。
実施例7に示す方法に従って合成した[125I]BIP-NMe2、[125I]BIP-OMe及び[125I]BIP-Meの各化合物を10体積%エタノール及び0.1体積%Tween80を含む生理食塩水で希釈した。1群5匹の5週齢ddY系雄性マウス(26-28g)に、尾静脈より1匹あたり19.6-29.4kBq(100μL)の各放射性ヨウ素標識BIP誘導体化合物を投与し、2、10、30、60分後に屠殺、採血後、臓器を取り出し、重量と放射能を測定した。
また、上記スキーム2に示す方法に従い、7-アミノ-3-トリブチルスタニルピリド[1,2-a]ベンゾイミダゾール、7-メチルアミノ-3-トリブチルスタニルピリド[1,2-a]ベンゾイミダゾール、7-ジメチルアミノ-3-トリブチルスタニルピリド[1,2-a]ベンゾイミダゾール、7-メトキシ-3-トリブチルスタニル-ピリド[1,2-a]ベンゾイミダゾール、7-メチル-3-トリブチルスタニルベンゾ[4,5]イミダゾ[1,2-a]ピリジンをそれぞれ合成し、実施例7の方法に従って、7-アミノ-3-[125I]ヨードピリド[1,2-a]ベンゾイミダゾール、7-メチルアミノ-3-[125I]ヨードピリド[1,2-a]ベンゾイミダゾール、7-ジメチルアミノ-3-[125I]ヨードピリド[1,2-a]ベンゾイミダゾール、7-メトキシ-3-[125I]ヨードピリド[1,2-a]ベンゾイミダゾール、7-メチル-3-[125I]ヨードベンゾ[4,5]イミダゾ[1,2-a]ピリジンをそれぞれ得る。
得られた125I標識化合物を用いて評価1に示す方法に従いインビトロオートラジオグラフィー評価を行って、AD脳内に蓄積したタウに対する結合選択性を有することを確認する。また、これら125I標識化合物を用いて評価2に示す方法に従い正常マウス体内放射能分布評価を行って、脳移行性及びその後の脳からの消失を確認する。
Claims (9)
- 前記放射性ハロゲン原子は、放射性ヨウ素原子である、請求項1に記載の放射性ハロゲン標識化合物又はその塩。
- 前記放射性ヨウ素原子が、123I、124I、125I又は131Iである、請求項2に記載の放射性ハロゲン標識化合物又はその塩。
- 前記一般式(1)中、R1が放射性ハロゲン原子であり、R2が炭素数1~4のアルキル基、炭素数1~4のアルコキシ基又は炭素数2~4のジアルキルアミノ基である、請求項1乃至3いずれか一項に記載の放射性ハロゲン標識化合物又はその塩。
- 請求項1乃至4いずれか1項に記載された放射性ハロゲン標識化合物又はその塩を含む、放射性医薬。
- 単光子放出コンピューター断層撮影(SPECT)に用いられる、請求項5に記載の放射性医薬。
- 請求項1乃至4いずれか1項に記載された放射性ハロゲン標識化合物又はその塩を含む、アルツハイマー病診断剤。
- 下記一般式(2):
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15/543,849 US10081630B2 (en) | 2015-08-19 | 2016-02-24 | Radioactive halogen-labeled pyrido [1,2-A] benzimidazole derivative compound |
EP16836812.4A EP3339309B1 (en) | 2015-08-19 | 2016-02-24 | Radioactive halogen-labeled pyrido[1,2-a]benzimidazole derivative compound |
CA2973864A CA2973864A1 (en) | 2015-08-19 | 2016-02-24 | Radioactive halogen-labeled pyrido[1,2-a]benzimidazole derivative compound |
KR1020177015494A KR20180037916A (ko) | 2015-08-19 | 2016-02-24 | 방사성 할로겐 표지 피리도[1,2-a]벤즈이미다졸 유도체 화합물 |
CN201680005442.2A CN107108616A (zh) | 2015-08-19 | 2016-02-24 | 经放射性卤素标记的吡啶并[1,2‑a]苯并咪唑衍生物化合物 |
JP2017535245A JP6609868B2 (ja) | 2015-08-19 | 2016-02-24 | 放射性ハロゲン標識ピリド[1,2−a]ベンゾイミダゾール誘導体化合物 |
AU2016308145A AU2016308145A1 (en) | 2015-08-19 | 2016-02-24 | Radioactive halogen-labeled pyrido(1,2-a)benzimidazole derivative compound |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2015161472 | 2015-08-19 | ||
JP2015-161472 | 2015-08-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2017029820A1 true WO2017029820A1 (ja) | 2017-02-23 |
Family
ID=58051575
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2016/055357 WO2017029820A1 (ja) | 2015-08-19 | 2016-02-24 | 放射性ハロゲン標識ピリド[1,2-a]ベンゾイミダゾール誘導体化合物 |
Country Status (9)
Country | Link |
---|---|
US (1) | US10081630B2 (ja) |
EP (1) | EP3339309B1 (ja) |
JP (1) | JP6609868B2 (ja) |
KR (1) | KR20180037916A (ja) |
CN (1) | CN107108616A (ja) |
AU (1) | AU2016308145A1 (ja) |
CA (1) | CA2973864A1 (ja) |
TW (1) | TW201707726A (ja) |
WO (1) | WO2017029820A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018164184A1 (ja) * | 2017-03-10 | 2018-09-13 | 国立大学法人滋賀医科大学 | 神経難病の画像診断薬及び体外診断薬 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2012521988A (ja) * | 2009-03-23 | 2012-09-20 | シーメンス メディカル ソリューションズ ユーエスエー インコーポレイテッド | 神経学的障害を検知するためのイメージング剤 |
JP2013522365A (ja) * | 2010-03-23 | 2013-06-13 | シーメンス メディカル ソリューションズ ユーエスエー インコーポレイテッド | 神経性疾患の検出のためのイメージング剤 |
JP2015517572A (ja) * | 2012-05-22 | 2015-06-22 | イーライ リリー アンド カンパニー | 神経機能障害を検出するための造影剤 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8932557B2 (en) | 2008-02-14 | 2015-01-13 | Eli Lilly And Company | Imaging agents for detecting neurological dysfunction |
JP5073871B2 (ja) | 2010-03-01 | 2012-11-14 | 日本メジフィジックス株式会社 | 放射性ヨウ素標識有機化合物またはその塩 |
JP2013237655A (ja) | 2012-05-17 | 2013-11-28 | Kyoto Univ | コンフォメーション病診断用分子プローブ |
JP6260967B2 (ja) * | 2013-11-06 | 2018-01-17 | 国立大学法人京都大学 | 放射性ヨウ素標識化合物、及び、これを含む放射性医薬 |
-
2015
- 2015-09-04 TW TW104129331A patent/TW201707726A/zh unknown
-
2016
- 2016-02-24 JP JP2017535245A patent/JP6609868B2/ja not_active Expired - Fee Related
- 2016-02-24 WO PCT/JP2016/055357 patent/WO2017029820A1/ja active Application Filing
- 2016-02-24 US US15/543,849 patent/US10081630B2/en not_active Expired - Fee Related
- 2016-02-24 KR KR1020177015494A patent/KR20180037916A/ko unknown
- 2016-02-24 AU AU2016308145A patent/AU2016308145A1/en not_active Abandoned
- 2016-02-24 CA CA2973864A patent/CA2973864A1/en not_active Abandoned
- 2016-02-24 CN CN201680005442.2A patent/CN107108616A/zh active Pending
- 2016-02-24 EP EP16836812.4A patent/EP3339309B1/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2012521988A (ja) * | 2009-03-23 | 2012-09-20 | シーメンス メディカル ソリューションズ ユーエスエー インコーポレイテッド | 神経学的障害を検知するためのイメージング剤 |
JP2013522365A (ja) * | 2010-03-23 | 2013-06-13 | シーメンス メディカル ソリューションズ ユーエスエー インコーポレイテッド | 神経性疾患の検出のためのイメージング剤 |
JP2015517572A (ja) * | 2012-05-22 | 2015-06-22 | イーライ リリー アンド カンパニー | 神経機能障害を検出するための造影剤 |
Non-Patent Citations (1)
Title |
---|
KENJI MATSUMURA ET AL.: "Alzheimer-byo Nonai Tau no Seitai Imaging o Mokuteki to shita Shinki Hoshasei Yoso Hyoshiki Benzoimidazopylidin Yudotai no Kaihatsu", ABSTRACTS OF 135TH ANNUAL MEETING OF PHARMACEUTICAL SOCIETY OF JAPAN, vol. 2, no. 26W- pml8S, 5 March 2015 (2015-03-05), pages 258, XP009509267 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018164184A1 (ja) * | 2017-03-10 | 2018-09-13 | 国立大学法人滋賀医科大学 | 神経難病の画像診断薬及び体外診断薬 |
Also Published As
Publication number | Publication date |
---|---|
EP3339309A1 (en) | 2018-06-27 |
CA2973864A1 (en) | 2017-02-23 |
TW201707726A (zh) | 2017-03-01 |
JP6609868B2 (ja) | 2019-11-27 |
CN107108616A (zh) | 2017-08-29 |
EP3339309B1 (en) | 2020-04-29 |
AU2016308145A1 (en) | 2017-08-03 |
JPWO2017029820A1 (ja) | 2018-06-07 |
US10081630B2 (en) | 2018-09-25 |
US20170362226A1 (en) | 2017-12-21 |
EP3339309A4 (en) | 2019-03-20 |
KR20180037916A (ko) | 2018-04-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6254126B2 (ja) | 造影剤およびその中間体を合成するための方法および装置 | |
JP2008546804A (ja) | 造影剤として用いるためのリガンドの放射性標識ペグ化 | |
WO2020065045A1 (en) | Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of psma-expressing cancers | |
BRPI0808503B1 (pt) | Composto, uso de um composto, e, composição farmacêutica | |
Srivastava et al. | Design, synthesis and biological evaluation of methyl-2-(2-(5-bromo benzoxazolone) acetamido)-3-(1 H-indol-3-yl) propanoate: TSPO ligand for SPECT | |
JP6609868B2 (ja) | 放射性ハロゲン標識ピリド[1,2−a]ベンゾイミダゾール誘導体化合物 | |
JP2013237655A (ja) | コンフォメーション病診断用分子プローブ | |
JP6609866B2 (ja) | 放射性ヨウ素標識ピリド[1,2−a]ベンゾイミダゾール誘導体化合物 | |
JP2016079108A (ja) | 放射性ヨウ素標識スチリル置換芳香族ヘテロ環化合物 | |
CN107406419B (zh) | Pet显像剂 | |
Cao et al. | Synthesis and preliminary evaluation of 131 I-9-iodovinyl-tetrabenazine targeting vesicular monoamine transporter 2 | |
US20180064742A1 (en) | Pet imaging tracer for imaging prostate cancer | |
JP7284490B2 (ja) | モノアミンオキシダーゼbイメージングプローブ | |
JP7024960B2 (ja) | Bcr-Ablタンパク質イメージング用分子プローブ | |
WO2014132919A1 (ja) | 診断用組成物 | |
JP6041751B2 (ja) | スチリルピリジン誘導体化合物 | |
WO2019216223A1 (ja) | 心疾患の非侵襲的画像診断剤 | |
KR20130121830A (ko) | 동위원소 탄소 콜린 유사체 | |
KR20210052435A (ko) | 방사성 이미다조티아디아졸 유도체 화합물 | |
JP2014218454A (ja) | スチリルピリジン誘導体化合物 | |
JP2012207995A (ja) | 脳内ノルエピネフリン・トランスポータを標的とする放射性臭素標識pet分子イメージングプローブ |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 16836812 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 20177015494 Country of ref document: KR Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2017535245 Country of ref document: JP Kind code of ref document: A Ref document number: 2973864 Country of ref document: CA |
|
REEP | Request for entry into the european phase |
Ref document number: 2016836812 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 15543849 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 2016308145 Country of ref document: AU Date of ref document: 20160224 Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |